Review on Study of Nanoparticles in Brain Targeting for Treatment Of Alzheimer’s
Abstract
Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder, in which there is a progressive deterioration of intellectual and social functions, memory loss, personality changes and inability for self-care, and has become the fourth leading cause of death in developed countries. Pathogenesis of AD, there is a progressive deposition of β-amyloid (Aβ)- peptide in the hippocampal and cerebral cortical regions. This deposition is associated with the presence of neurofibrillary tangles (NFTs) and senile plaques. The senile plaques deposited between the neurons consist mainly protein β amyloid. Neurofibrillary tangles deposited inside the neurons fabricated from Tau protein. Diagnosing Alzheimer's requires careful medical evaluation thorough medical history, mental status testing, physical and neurological examination tests (such as blood tests and brain imaging), two classes of medications approved to treat AD. Cholinesterase inhibitors: Donepezil, Rivastigmine, Galantamine, NMDA receptor antagonists: Memantine. The major goal in designing nanoparticles as a delivery system are to control particle size, surface property and release of pharmacologically active agents in order to achieve the site-specific action of the drug at the therapeutic optimum rate and dose regimen of the agent to the CNS, but also the ability of the agent to access the relevant target site within the CNS. Many strategies have been developed to deliver the drug into brain by crossing the BBB: chemical delivery systems, magnetic drug targeting or drug carrier systems such as antibodies, liposomes or nanoparticles. Among those, nanoparticles have got a great concentration as the potential targeted drug delivery systems in the brain recently.
Keywords: Alzheimer’s disease, β-amyloid, cholinesterase inhibitors, Curcumin nanoparticles.
Keywords:
Alzheimer’s disease, β-amyloid, cholinesterase inhibitors, Curcumin nanoparticlesDOI
https://doi.org/10.22270/jddt.v14i6.6600References
Chang DH, Tang XC. Comparative studies of Huprazine A, E2020 and Tacrine on behaviour and cholinesterase activities. Pharmacol Biopchem Behav. 1998; 60:377- 86. https://doi.org/10.1016/S0091-3057(97)00601-1 PMid:9632220
Kosasa T, Kuriya Y, Matsui K, Yarnanishi Y. Inhibitory effect of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. Eur J Pharmacol. 1999; 386:7-13. https://doi.org/10.1016/S0014-2999(99)00741-4 PMid:10611458
Mir Najib Ullah SN, Afzal O, Altamimi A S Ather H, Sultana S, Almalki WH, Bharti P, Sahoo A, Dwivedi K, Khan G, Sultana S. Nanomedicines in the management of Alzheimer's disease: State -of-the-art. Biomedicines. 2023 Jun 18: 11(6): 1752. https://doi.org/10.3390/biomedicines11061752 PMid:37371847 PMCid:PMC10296528
Puranik N, Yadav D, Song M. Advancement in the Applications of Nanomedicines in Alzheimer's Disease: A therapeutic Perspective. Int. j. Mol. Sci. 2023 Sep 13: 24(18): 14044. https://doi.org/10.3390/ijms241814044 PMid:37762346 PMCid:PMC10530821
Zhang HY. One-compound-multiple targets strategy to combat Alzheimer's disease. FEBS Lett. 2005; 579: 5260-4. https://doi.org/10.1016/j.febslet.2005.09.006 PMid:16194540
Agamanolis DP. Neuropathology. NEOMED; 2011. [Updated June 2014; cited 2011] Available from: http://neuropathology-web.org/chapter9/chapter9bAD.html [Last accessed on 5 Feb 2016]
United States postal service; June 2008. Available from: http://www.nia.nih.gov/NR/rdonlyres/A01D12CE-17E3-4D3D-BCEF-9ABC4FF91900/0/TANGLES_HIGH.JPG [Last accessed on 30 Jan 2016]
Chang DH, Tang XC. Comparative studies of Huprazine A, E2020 and Tacrine on behavior and cholinesterase activities. Pharmacol Biopchem Behav. 1998; 60; 377-86. https://doi.org/10.1016/S0091-3057(97)00601-1 PMid:9632220
Khan NH, Mir M, Ngowi EE, Zafar U, Khakwani MM, Khattak S, Zhai YK, Jiang ES, Zheng M, Duan SF, Wei JS. Nanomedicine: A Promising way to manage Alzheimer's disease. Front. Bioeng. Biotechnol. 2021 Apr 9; 9:630055. https://doi.org/10.3389/fbioe.2021.630055 PMid:33996777 PMCid:PMC8120897
NIH meeting advances Alzheimer's research agenda. Global health matters newsletter 2015; 14(2):1-12. Available from: http://www.fic.nih.gov/News/GlobalHealthMatters/march-april-2015/Documents/fogarty-nih-global-health-matters-newsletter-march-april-2015.pdf [Last accessed on 10 Feb 2016]
Alzheimer's statistics, Alzheimer's.net, 2016. [available from 2000;update 2016]Available from: http://www.alzheimers.net/resources/alzheimers-statistics [Last accessed on 31 Jan 2016]
Zhang HY. One-compound-multiple targets strategy to combat Alzheimer's disease. FEBS Lett. 2005; 579: 5260-4. https://doi.org/10.1016/j.febslet.2005.09.006 PMid:16194540
Agamanolis DP. Neuropathology. NEOMED; 2011. [Updated June 2014; cited 2011] Availablefrom:http://neuropathology-web.org/chapter9/chapter9bAD.html [Last accessed on 5 Feb 2016]
United States postal service; June2008. Available from: http://www.nia.nih.gov/NR/rdonlyres/A01D12CE-17E3-4D3D-BCEF-9ABC4FF91900/0/TANGLES_HIGH.JPG [Last accessed on 30 Jan 2016]
Brauner DJ, Muir JC, Sachs GA. Treating non dementia illnesses in patient with dementia. J Am Med Assoc. 2000; 283(24): 3230-5. https://doi.org/10.1001/jama.283.24.3230 PMid:10866871
Slattum PW, Johnson MA. Caregiver burden in Alzheimer's disease. Consult Pharm. 2004; 19(4): 352-62. https://doi.org/10.4140/TCP.n.2004.352 PMid:16553479
Mohamed S, Rosenheck R, Lyketsos K. Caregiver burden in Alzhimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry. 2010; 18(10): 917-27. https://doi.org/10.1097/JGP.0b013e3181d5745d PMid:20808108 PMCid:PMC3972419
Parihar MS, Hemnani T. Alzheimer's diseasepathogesis and therapeutic interventions. J Clin Neurosci. 2004; 11(5): 456-67. https://doi.org/10.1016/j.jocn.2003.12.007 PMid:15177383
Clark CM, Karlawish JM. Alzheimer's disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med. 2003; 138(5): 400-10. https://doi.org/10.7326/0003-4819-138-5-200303040-00010 PMid:12614093
Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000; 60(5): 1095-122.https://doi.org/10.2165/00003495-200060050-00008 PMid:11129124
Information on Aricept®, Pfizer. Available from: www.aricept.com/ [Last accessed on 15 Feb 2016]
Black SE, Doody R, Li H. Donepezil preserves cognition and global function in patient with severe Alzheimer disease. Neurol. 2007;69(5): 459-69. https://doi.org/10.1212/01.wnl.0000266627.96040.5a PMid:17664405
Gautheir S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drug Aging. 2001;18(11): 853-62. https://doi.org/10.2165/00002512-200118110-00006 PMid:11772125
Information on Exelon®. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/Exelon.pdf [Last accessed on 15 Feb 2016]
Alzheimer's disease medications. NIH publication; Nov 2008. [Updated Jan 2014] Available from: www.nia.nih.gov/.../alzheimers_disease_fact_sheet_0.pdf [Last accessed on 15 Feb 2016]
Information on Razadyne® ER, Ortho-McNeil Neurologics Inc. Available from: www.ortho-mcneilneurologics.com/products_razadyneer.html [Last accessed on 31 Jan 2016]
Seltzer B. Galantamine-er for the treatment of mild-to-moderate Alzheimer's disease. Clin Interv Aging. 2010; 5: 1-6. https://doi.org/10.2147/CIA.S4819
Winblad B, Poritis N. Memantine in severe dementia: results of the M- best study (benefit and efficiency in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999; 14: 135-46. https://doi.org/10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0
Reiseberg B, Doody R, Stoffler A. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41. https://doi.org/10.1056/NEJMoa013128 PMid:12672860
Tariot PN, Farlow MR, Grossberg GT. Memantine treatment in patiens with moderate to severe Alzheimer disease already Donepezil. A randomized controlled trial. J Am Med Assoc. 2004; 291: 317-24. https://doi.org/10.1001/jama.291.3.317 PMid:14734594
Thassu D, Pathak Y, Deleers M. Nanoparticulate drug delivery systems: An overview. Informa Healthcare USA, Inc; 2007. p. 1-33. https://doi.org/10.1201/9781420008449-1
Suphiya P, Ranjita M, Sanjeeb KS. Nanoparticles: a boom to drug delivery, therapeutics, diagnostics and imaging. Nanomed. 2011; 63(2): 1-20.
Sonal PA, Bhushan RR, Sunil BR, Sunil PP. Nano Suspension: At a Glance. Int J Pharm Sci. 2011; 3(1): 947-60.
Murray CB, Kagan CR. Synthesis and characterisation of monodisperse nanocrystals and close-packed nanocrystal assemblies. Annu Rev Mater Sci. 2000; 30: 545-610. https://doi.org/10.1146/annurev.matsci.30.1.545
Nagaraju P, Krishnachaithanya K, Srinivas VD, Padma SV. Nanosuspensions: A promising drug delivery systems. Int J Pharm Sci Nanotech. 2010; 2(4): 679-84. https://doi.org/10.37285/ijpsn.2009.2.4.1
Dheivanai S L, Jeevaprakash G, Nallathambi R, Selva Kumar S, Senthilvelan S. Formulation, development and evaluation of Abacavir loaded polymethacrylic acid nanoparticles. Int J Pharm. 2012; 3(3): 265-7.
Kopecek J. Smart and genetically engineered biomaterials and drug delivery systems. Eur J Pharm Biopharm. 2003; 20: 1-16. https://doi.org/10.1016/S0928-0987(03)00164-7 PMid:13678788
Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001; 73: 137-72. https://doi.org/10.1016/S0168-3659(01)00299-1 PMid:11516494
Muller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm. 2004; 58: 343-56. https://doi.org/10.1016/j.ejpb.2004.03.028 PMid:15296960
Sunitha R, Harika D, Kumar AP, Prabha KS, Prasanna PM. A review: nanoparticles as specified carriers in targeted brain drug delivery system. Am J Pharm Res. 2011; 1(2): 121-34.
Bala SH, Kumar MN. Plga nanoparticles in drug delivery: The state of the art. Crit Rev Ther Drug Carrier Syst. 2004; 21(5): 387-422. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v21.i5.20 PMid:15719481
Kumar MS, Santhi K. Targeted delivery of tacrine into brain with polysorbate80- coated poly (n-butylcynoacrylate) nanoparticles. Eur J Pharm Biopharm. 2008 ;(70): 75-84. https://doi.org/10.1016/j.ejpb.2008.03.009 PMid:18472255
Vidyavathi M, Sandya P, Sarika B. Nanotechnology in Development of Drug Delivery System. Int J Pharm Sci Res. 2012; 3(1): 84-96.
Kreuter J. Nanoparticles as drug delivery system, Encyclopedia of nanoscience and nanotechnology, H. S. Nalwa (Editor), American Scientific Publishers, Stevenson Ranch, Calif., 2004: 161-8
Nahar M, Dutta T, Murugesan S, Asthana A, Mishra D, Rajkumar V et al.Functional polymeric nanoparticles: An efficient and promising tool for active delivery of bioactive. Crit Rev Ther Drug Carrier Syst. 2006;23(4): 259-318. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v23.i4.10 PMid:17341200
Sai Hunuman sag. "NANOPARTICLES" pharmmainfo.net. [Accessed on 31 Jan 2016].
Vyas SP, Khar RK. Targeted and controlled drug delivery- novel carrier system. 2nd ed. New Delhi: CBS Publishers; 2002. p. 331-81.
Ekambaram P, Sathali AH, Priyanka K. Solid Lipid Nanoparticles: a Review. Sci Rev Chemic Commun. 2012;2(l): 80-102.
Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saaettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238: 241-5. https://doi.org/10.1016/S0378-5173(02)00080-7 PMid:11996827
Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for brain targeted brain drug delivery. Adv Drug Del Rev. 2007;59(6): 454-77. https://doi.org/10.1016/j.addr.2007.04.011 PMid:17570559
Rupenagunta A, Somasundaram I, Ravichandiram V, Kausalya J. Solid lipid nanoparticles-a versatile carrier system. J Pharma Res. 2011;4(7): 2069-75.
Fahr A, Liu X. Drug delivery strategies for poorly water soluble drugs. Expert Opin Drug Del. 2007;4(4): 403-16. https://doi.org/10.1517/17425247.4.4.403 PMid:17683253
Yadav P, Soni G, Mahor R, Alok S, Singh P, Verma A. Solid lipid nanoparticles: an effective and promising drug delivery system- a review. Int J Pharm Sci Res. 2014;5(3): 1152-62.
Mukherjee S, Ray S, Thakur R. Solid lipid nanoparticles: A modern formulation approach in drug delivery. Indian J Pharm Sci. 2009;71(4): 349-58.
https://doi.org/10.4103/0250-474X.57282 PMid:20502539 PMCid:PMC2865805
Schwarz C, Mehnert W, Lucks J, Muller R. Solid lipid nanoparticles (SLN) for controlled drug delivery I. Production characterization and sterilization. J Control Res. 1994;30(1): 83-96. https://doi.org/10.1016/0168-3659(94)90047-7
Published



How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).